Effectiveness of the Crizotinib Therapeutic Management Guide in Communicating Risks, and Recommended Actions to Minimize Risks, Among Physicians Prescribing Crizotinib in Europe

Introduction To support a positive benefit/risk profile for crizotinib, additional risk minimization measures (RMMs) included a patient information brochure (PIB) and a therapeutic management guide (TMG) to inform patients and physicians in Europe about the risks associated with crizotinib. This study evaluated the effectiveness of the TMG in communicating risks associated with crizotinib.